Last reviewed · How we verify
QL0911
QL0911 is a small molecule drug that targets the SGLT2 receptor.
QL0911 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | QL0911 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
QL0911 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (PHASE3)
- QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (PHASE2, PHASE3)
- Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (PHASE2, PHASE3)
- Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia (PHASE2, PHASE3)
- Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |